Anti-HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B
- PMID: 36732913
- DOI: 10.1111/liv.15536
Anti-HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B
Comment in
-
Reply to the letter "Anti-HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B".Liver Int. 2023 Apr;43(4):949. doi: 10.1111/liv.15551. Epub 2023 Mar 8. Liver Int. 2023. PMID: 36825356 No abstract available.
Comment on
-
Low anti-HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen-negative patients.Liver Int. 2022 Dec;42(12):2674-2682. doi: 10.1111/liv.15433. Epub 2022 Oct 5. Liver Int. 2022. PMID: 36152268
References
REFERENCES
-
- Ohlendorf V, Wübbolding M, Gineste P, et al. Low anti-HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen-negative patients. Liver Int. 2022;00:1-9.
-
- Chi H, Li Z, Hansen BE, et al. Serum level of antibodies against hepatitis B Core protein is associated with clinical relapse after discontinuation of Nucleos(t)ide analogue therapy. Clin Gastroenterol Hepatol. 2019;17:182-191.
-
- Tseng CH, Hsu YC, Chang CY, et al. Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B. J Formos Med Assoc. 2018;117:915e921.
-
- Su T-H, Yang HC, Tseng TC, et al. Distinct relapse rates and risk predictors after discontinuing Tenofovir and Entecavir therapy. J Infect Dis. 2018;217:1193-1201.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
